May 7, 2013
Mochida Pharmaceutical announced on April 25 that it has filed a new drug application (NDA) for its investigational prostaglandin I 2 preparation treprostinil for the treatment of pulmonary arterial hypertension (PAH). Treprostinil, launched in the US in 2002 under the...read more